Drug Approval | August 17, 2021
Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
The approval allows it to market its products in the country
The approval allows it to market its products in the country
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated
